Montanova Capital LLC Has $1.96 Million Position in Johnson & Johnson $JNJ

Key Points

• Montanova Capital reduced its Johnson & Johnson position by 67.1% in the second quarter, selling 15,700 shares and retaining 7,700 shares valued at approximately $1.96 million. Institutional investors collectively own 69.55% of JNJ.
• Johnson & Johnson reported better-than-expected quarterly results, with EPS of $2.90 and revenue of $25.31 billion, up 6.6% year over year. Management maintained fiscal 2026 EPS guidance of $11.60–$11.75.
• Shares trade near their 52-week high at roughly 31 times earnings, while the company offers a $1.34 quarterly dividend, equivalent to a 2.0% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $272.83.

Montanova Capital LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 67.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,700 shares of the company's stock after selling 15,700 shares during the quarter. Montanova Capital LLC's holdings in Johnson & Johnson were worth $1,956,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. Elefante Mark B increased its holdings in shares of Johnson & Johnson by 9.8% during the second quarter. Elefante Mark B now owns 28,686 shares of the company's stock worth $7,285,000 after buying an additional 2,563 shares in the last quarter. World Investment Advisors grew its position in Johnson & Johnson by 19.6% during the 4th quarter. World Investment Advisors now owns 161,343 shares of the company's stock worth $33,390,000 after acquiring an additional 26,450 shares during the last quarter. Signal Advisors Wealth LLC grew its position in Johnson & Johnson by 76.1% during the 1st quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company's stock worth $3,697,000 after acquiring an additional 6,539 shares during the last quarter. Gradient Investments LLC increased its holdings in Johnson & Johnson by 9.9% during the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company's stock valued at $38,815,000 after purchasing an additional 13,737 shares in the last quarter. Finally, Louisiana State Employees Retirement System bought a new position in Johnson & Johnson in the 1st quarter valued at $30,017,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: At the Wells Fargo Healthcare Conference, Johnson & Johnson highlighted growth opportunities in MedTech, with cardiovascular products taking center stage. Management’s focus on high-end, innovative devices supports the company’s longer-term growth outlook. Johnson & Johnson Eyes High-End MedTech Growth as Cardiovascular Takes Center Stage
• Positive Sentiment: JNJ is preparing to present 24 abstracts at Psych Congress 2026, including pivotal Phase 3 CAPLYTA data in bipolar mania and new SPRAVATO analyses. The data could strengthen confidence in the company’s neuropsychiatry pipeline and future pharmaceutical growth. Johnson & Johnson Neuropsychiatry Data
• Positive Sentiment: Jim Cramer characterized the recent weakness as a buying opportunity, reinforcing the view that JNJ’s defensive profile, diversified healthcare operations, and dividend appeal may attract investors during market uncertainty. Cramer Says It’s Time to Buy the Dip on JNJ
• Neutral Sentiment: Analysts and market commentary continue to view JNJ as a defensive stock ahead of inflation data and the Federal Reserve’s next rate decision. That positioning may support demand, but macroeconomic uncertainty is also increasing day-to-day volatility. Defensive Stocks Ahead of CPI and the Fed
• Negative Sentiment: JNJ recently declined more than the broader market, suggesting profit-taking or increased sensitivity to market-wide selling. With shares near their 52-week high and trading at roughly 31 times earnings, valuation may be limiting near-term upside despite solid earnings and full-year EPS guidance. Johnson & Johnson Sees a More Significant Dip Than the Broader Market

Johnson & Johnson Price Performance

JNJ opened at $267.20 on Thursday. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12 month low of $173.33 and a 12 month high of $281.07. The company has a fifty day simple moving average of $262.88 and a 200 day simple moving average of $245.62. The stock has a market cap of $643.93 billion, a P/E ratio of 30.96, a P/E/G ratio of 2.57 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm had revenue of $25.31 billion during the quarter, compared to analysts' expectations of $25.06 billion. During the same period in the previous year, the firm earned $2.77 earnings per share. The company's revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, research analysts expect that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.0%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson's dividend payout ratio (DPR) is 62.11%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on JNJ shares. HSBC set a $290.00 target price on Johnson & Johnson and gave the company a "buy" rating in a research note on Monday, July 6th. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a research note on Monday, August 3rd. Royal Bank Of Canada lifted their target price on Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Weiss Ratings upgraded Johnson & Johnson from a "buy (b-)" rating to a "buy (b)" rating in a research report on Friday, July 24th. Finally, Scotiabank reiterated an "outperform" rating and issued a $305.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $272.83.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares of the company's stock, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of the company's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares of the company's stock, valued at $51,210,615.36. This trade represents a 7.16% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 87,569 shares of company stock valued at $23,064,544. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.